Cargando…

Whole Tumor Antigen Vaccines: Where Are We?

With its vast amount of uncharacterized and characterized T cell epitopes available for activating CD4(+) T helper and CD8(+) cytotoxic lymphocytes simultaneously, whole tumor antigen represents an attractive alternative source of antigens as compared to tumor-derived peptides and full-length recomb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiang, Cheryl Lai-Lai, Coukos, George, Kandalaft, Lana E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494356/ https://www.ncbi.nlm.nih.gov/pubmed/26343191 http://dx.doi.org/10.3390/vaccines3020344

Ejemplares similares

Autologous whole-tumor antigen vaccination in combination with adoptive T cell therapy for patients with recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2013)

Day-4 Myeloid Dendritic Cells Pulsed with Whole Tumor Lysate Are Highly Immunogenic and Elicit Potent Anti-Tumor Responses
por: Chiang, Cheryl Lai-Lai, et al.
Publicado: (2011)

Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human
por: Chiang, Cheryl Lai-Lai, et al.
Publicado: (2021)

Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?
por: Martin Lluesma, Silvia, et al.
Publicado: (2018)

A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2013)

Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors
por: Yakkala, Chakradhar, et al.
Publicado: (2019)

Clinical translation section: accelerating the pace from bench to bedside
por: Kandalaft, Lana E, et al.
Publicado: (2011)

Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity
por: Fritah, Hajer, et al.
Publicado: (2023)

Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate
por: Chiang, Cheryl L-L, et al.
Publicado: (2011)

Cancer Vaccines in Ovarian Cancer: How Can We Improve?
por: Martin Lluesma, Silvia, et al.
Publicado: (2016)

Updates on Dengue Vaccine and Antiviral: Where Are We Heading?
por: Norshidah, Harun, et al.
Publicado: (2021)

Whole tumor antigen vaccination using dendritic cells: Comparison of RNA electroporation and pulsing with UV-irradiated tumor cells
por: Benencia, Fabian, et al.
Publicado: (2008)

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2012)

Hepatitis C Vaccination: Where We Are and Where We Need to Be
por: Manne, Vignan, et al.
Publicado: (2021)

Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go?
por: Ottenhoff, Tom H. M., et al.
Publicado: (2012)

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
por: Kandalaft, Lana E., et al.
Publicado: (2013)

Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers
por: Kandalaft, Lana E., et al.
Publicado: (2021)

Chronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?
por: Hayes, Gemma E., et al.
Publicado: (2016)

Schistosomiasis vaccines: where do we stand?
por: Tebeje, Biniam Mathewos, et al.
Publicado: (2016)

Vaccines against Genital Herpes: Where Are We?
por: Kim, Hyeon Cheol, et al.
Publicado: (2020)

Vaccine for Diabetes—Where Do We Stand?
por: Chellappan, Dinesh Kumar, et al.
Publicado: (2022)

Vaccines against Tuberculosis: Where Are We Now?
por: Srivastava, Shruti, et al.
Publicado: (2023)

Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity
por: Bassani-Sternberg, Michal, et al.
Publicado: (2017)

Nanoparticles in the environment: where do we come from, where do we go to?
por: Bundschuh, Mirco, et al.
Publicado: (2018)

Animal Sentience: Where are We and Where are We Heading?
por: Proctor, Helen
Publicado: (2012)

Bioactive Glasses: Where Are We and Where Are We Going?
por: Baino, Francesco, et al.
Publicado: (2018)

Diabetic cardiomyopathy: where we are and where we are going
por: Lee, Wang-Soo, et al.
Publicado: (2017)

Hidradenitis Suppurativa: Where We Are and Where We Are Going
por: Scala, Emanuele, et al.
Publicado: (2021)

Rate of Freeze Impacts the Survival and Immune Responses Post Cryoablation of Melanoma
por: Yakkala, Chakradhar, et al.
Publicado: (2021)

COVID-19 Vaccination. Where Are We and Where Should We Go?
por: Peña-Otero, David
Publicado: (2022)

Vesicoureteral Reflux: Where Have We Been, Where Are We Now, and Where Are We Going?
por: McLorie, Gordon A.
Publicado: (2008)

Colon Capsule Endoscopy: Where Are We and Where Are We Going
por: Han, Yoo Min, et al.
Publicado: (2016)

Accommodative intraocular lenses: where are we and where we are going
por: Alió, Jorge L., et al.
Publicado: (2017)

Osteoarthritis and Diabetes: Where Are We and Where Should We Go?
por: Alenazi, Aqeel M., et al.
Publicado: (2023)

Biomarkers of Neonatal Sepsis: Where We Are and Where We Are Going
por: Boscarino, Giovanni, et al.
Publicado: (2023)

The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?
por: Werner, Rudolf A., et al.
Publicado: (2018)

Obstetric ultrasound: where are we and where are we going?
por: Abramowicz, Jacques S
Publicado: (2021)

Research Integrity: Where We Are and Where We Are Heading
por: Zhaksylyk, Alikhan, et al.
Publicado: (2023)

Pneumococcal vaccination in older persons: where are we today?
por: Van Buynder, Paul, et al.
Publicado: (2018)

Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes
por: Adams, Sarah F, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c0phe0n39rfie0e3dk6eo7nqdg